首页> 外文会议>Lancefield International Symposium on Streptococci and Streptococcal Diseases >Oral streptococcal BLIS: Heterogeneity of the effector molecules and potential role in the prevention of streptococcal infections
【24h】

Oral streptococcal BLIS: Heterogeneity of the effector molecules and potential role in the prevention of streptococcal infections

机译:口服链球菌蓝斑:效应分子的异质性和在预防链球菌感染中的潜在作用

获取原文

摘要

Streptococci commonly produce bacteriocin-like inhibitory substances (BLIS). Inhibitory molecules characterized to date have included members of bacteriocin classes I, II and HI. Streptococcus salivarius. Streptococcus mutans and Streptococcus uberis strains frequently produce multiple bacteriocins of these various classes. Lantibiotics belonging to the streptococcin A-FF22 (S A-FF22) and salivaricin A (SalA) clusters are produced by several oral streptococcal species. Multi-bacteriocin-producing streptococci such as S. salivarius strain K12, which contain a variety of bacteriocin loci located on mega-plasmids, are now finding application as oral probiotics.
机译:链球菌通常产生含有细菌蛋白的抑制物质(BLIS)。迄今为止的抑制分子已包括细菌素类别I,II和HI的成员。链球菌唾液。链球菌和链球菌Uberis菌株经常产生这些各种阶级的多种菌丝。属于链球菌A-FF22和唾液蛋白A(SALA)簇的Lantibiotics由几种口服链球菌产生。产生多种细菌素的链球菌,例如含有位于Mega-质粒上的各种菌株基因座的S.唾液菌菌株K12,现在发现适用于口服益生菌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号